ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
42 announcements with these filters
Q2 FY27 consolidated revenue ₹47.1cr (+50% YoY), EBITDA ₹11.3cr (+65%), PAT ₹6.6cr (+30%). Capacity utilisation 46%. Parenterals facility pending commissioning.
Trident Lifeline Ltd reported revenue from operations of ₹80.8 Cr (+62.9% YoY) and net profit of ₹11.7 Cr (+85.7% YoY) for H1 FY27.
Trident Lifeline reported Q2 FY27 revenue of ₹47.1 Cr and PAT of ₹6.6 Cr, up 50% and 30% YoY. The release also mentions a proposed preferential issue.
Trident Lifeline's EGM on 27 October 2026 considered an articles alteration and preferential issues of equity and warrants. E-voting results are due within 48 working hours.
Trident Lifeline declared an interim dividend of Rs 0.50 per share for FY 2026-27. Record date is 30 October 2026, with payment by 25 November 2026.
Trident Lifeline Ltd reported revenue from operations of ₹80.8 Cr (+62.9% YoY) and net profit of ₹11.6 Cr (+58.9% YoY) for H1 FY27.
Trident Lifeline Ltd submitted its quarterly shareholding pattern disclosure in compliance with SEBI regulations. This routine filing presents the distribution of equity across various shareholder categories.
Trident Lifeline Limited scheduled a board meeting for October 26, 2026, to consider financial results for the half year ended September 30, 2026, and interim dividend.
Trident Lifeline has converted 24,000 equity warrants into 24,000 equity shares at a price of Rs. 266 per share, aggregating to Rs. 0.64 Crore.
Trident Lifeline allotted 24,000 equity shares upon conversion of warrants, receiving ₹0.48 Crore. This conversion reduces the number of pending warrants.
Trident Lifeline Limited issued a corrigendum to its EGM notice regarding a Rs.41.14 Crore preferential issue. The update rectifies UBO details and adds disclosures following BSE observations.
Trident Lifeline Limited has issued a corrigendum to its EGM notice regarding a preferential issue of shares and warrants. The amendment provides updated utilization details for proceeds totaling Rs. 57.98 Crore.
Trident Lifeline Limited participated in CPHI Milan 2026, aimed at expanding its presence and visibility in regulated pharmaceutical markets.
Trident Lifeline Ltd corrected clerical errors regarding investor names in Annexure I of the board meeting outcome dated October 5, 2026.
Trident Lifeline Ltd has issued a notice for an Extra-ordinary General Meeting on October 27, 2026, to consider capital issuance and amendments to the company's articles.
Trident Lifeline Ltd has scheduled an EGM for October 27, 2026, to seek approval for an alteration of Articles of Association and a preferential issue of shares.
Trident Lifeline Ltd has submitted its quarterly shareholding pattern as mandated by SEBI regulations for the period ended August 31, 2026.
Trident Lifeline Ltd's board approved a Rs. 57.98 Crore fundraise via preferential allotment of equity shares and convertible warrants. The issue includes shares for public investors and warrants for promoters.
Trident Lifeline Ltd acquired an additional 1% equity stake in its subsidiary, Trident Mediquip Limited, for approximately Rs. 0.95 Crore.
Trident Lifeline has scheduled a board meeting for October 5, 2026, to discuss a potential fund-raising proposal via equity or warrants and to schedule an EGM.
Trident Lifeline Ltd conducted its 13th Annual General Meeting on September 26, 2026, to approve financial statements, director re-appointment, and managerial remuneration proposals.
Trident Lifeline Limited clarified to the stock exchange that recent share price movements are purely market-driven, confirming no pending undisclosed material information.
Trident Lifeline Limited received an award from PHARMEXCIL for its contribution to India's pharmaceutical exports. This recognition highlights the company's growth in global markets.
Trident Lifeline Limited has scheduled its 13th Annual General Meeting for September 26, 2026. The company concurrently released its Annual Report for the financial year 2025-26.
Trident Lifeline Ltd has revised its Book Closure dates and e-voting Cut-off date for the 13th Annual General Meeting. New Book Closure begins September 20, 2026.
Trident Lifeline Limited allotted 24,000 equity shares upon conversion of warrants at ₹266 per share. This exercise increased the company's paid-up share capital.
Trident Lifeline allotted 24,000 equity shares upon the conversion of 24,000 warrants, aggregating Rs. 0.48 Crore. This allotment changes the company's paid-up equity share capital.
Trident Lifeline Ltd has been selected for the 'Outstanding Contribution to India's Pharmaceutical Exports' award by PHARMEXCIL. The award ceremony is scheduled for September 7, 2026.
Trident Lifeline Limited approved the Board’s Report for FY 2026 and the draft notice for its 13th AGM scheduled for September 26, 2026.
Trident Lifeline Limited announced it was featured in India Pharma Outlook magazine. The feature highlights the company's growth, business strengths, and strategic initiatives.